Munich - Delayed Quote • EUR Iovance Biotherapeutics Inc (2LB.MU) Follow 10.94 -0.05 (-0.50%) At close: April 26 at 8:03 AM GMT+2 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for 2LB.MU 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: 2LB.MU View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations 3 Millionaire-Maker Biotech Stocks 20 Counties with the Highest Cancer Rates in the US Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting These Biotech Stocks Could Soar 120% and 295%, According to Wall Street Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Is Iovance Biotherapeutics Stock a Buy Now? Market Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound? 2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies